ABSTRACT
This chapter presents information on classification & mode of action, indications & dermatological uses, formulations/presentation, dosages & suggested regimens, baseline investigations, considerations & monitoring, contraindications, cautions, important drug interactions, adverse effects & their management, use in special situations, and essential patient information of Ustekinumab. Ustekinumab is the first licensed biological therapy inhibiting the action of interleukin (IL)-12 and IL-23 for use in the treatment of moderate to severe psoriasis. Ustekinumab is licensed for the treatment of adults with moderate to severe plaque psoriasis or active psoriatic arthritis. In the treatment of psoriatic arthritis, ustekinumab is licensed both as monotherapy and in combination with methotrexate. The effect of ustekinumab on human fertility has not been evaluated but no adverse effect on male fertility has been observed in animal studies. Due to declining immune function and the increased risk of infections in the elderly population, caution is advised when treating this age group with biologic drugs including ustekinumab.
